CANCER IMMUNOTHERAPY MARKET ANALYSIS

Cancer Immunotherapy Market, By Therapy Type (Immune checkpoint inhibitors, Vaccines, Adoptive Cell Therapies, Immune System Modulators, Monoclonal antibodies, Oncolytic Virus Therapy), By Route of Administration (Subcutaneous, Oral, Intramuscular, Intravenous, Other), By Cancer Type (Lymphoma, Breast Cancer, Colorectal Cancer, Bladder Cancer, Skin Cancer, Lung Cancer, Kidney Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024
Code : CMI5274
Pages :168
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Developments

On March 14, 2024, Bristol Myers Squibb, a pharmaceutical company, announced that Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, had been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.
On March 07, 2024, Bristol Myers Squibb announced that the U.S. FDA had approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common kind of bladder cancer.
In December 2023, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation and Astellas Pharma Inc., a pharmaceutical company announced that the U.S. FDA had authorized PADCEV (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.
In February, 2023, the University of Vermont, Cancer Center launched CAR-T Cell program. Under this program, the UVM Cancer Center will offer a novel, highly effective form of cancer treatment called CAR T-cell therapy. The UVM Cancer Center will be the only health care institution in Vermont and northern New York to provide this treatment.